What is SkinTE?

SkinTE is a first-of-its-kind human cellular and tissue-based product derived from a patient’s own skin to regenerate full-thickness, functional skin with all its layers (epidermis, dermis and hypodermis) and appendages, including hair follicles and glands.

What are the intended uses of SkinTE?

SkinTE can be used by physicians and other medical providers to repair, reconstruct, replace or supplement a patient's damaged or missing skin tissue. It is currently being used by providers for the treatment of:

  • Wounds (acute & chronic)
  • Surgical reconstruction events
  • Burns (acute, subacute & burn reconstruction)
  • Scar revision
  • Traumatic injuries
  • Replacement of skin grafts or failed flap coverage

How is SkinTE used?

  1. Provider uses materials from the all-inclusive Harvest Box to take a small, full-thickness skin sample from the patient and return it to PolarityTE in the provided parcel.
  2. PolarityTE manufactures SkinTE.
  3. SkinTE is contained within a syringe and is returned to provider in all-inclusive Deployment Box as soon as same day, and typically within 48-72 hours based on providers’ requests.
  4. Provider applies SkinTE to patient’s wound/defect, covers with dressings and cares for wound/defect similar to standard of care for skin grafts.

How to receive treatment with SkinTE?

Whether an individual patient’s particular condition may be appropriate for treatment with SkinTE is a medical decision to be determined in consultation with a licensed and trained medical provider. To pursue treatment with SkinTE, patients should see their medical provider who can contact PolarityTE to obtain approval to use SkinTE at their desired health facility or refer to a medical provider or facility already approved for SkinTE treatment according to the specific case. SkinTE is currently only being used in the United States.

View SkinTE Brochure

How can medical providers access SkinTE for their patients?

Providers can contact PolarityTE directly at for more information about clinical use of SkinTE.

Still have more questions?

Tell us more below.

I am not a robot, to verify please answer 8+7 is equal to

We respect your privacy. We do not sell, rent, or loan any information to any third party. Any information you give us is held with the utmost care and security, and will be used only in ways to which you have consented.

About SkinTE™

SkinTE is a fully autologous (from the patient for the patient), homologous (utilized as a skin substrate) cutaneous construct which should only be used by skilled medical professionals.

SkinTE is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument.

SkinTE is processed and marketed in accordance with the FDA's requirements for human cellular, tissue, and cellular and tissue-based products, and current good tissue practices (21 CFR 1271).

Important Safety Information

Proper aseptic procedural and/or surgical handling is mandatory when using SkinTE. Failure to ensure proper aseptic technique may result in contamination of the tissue product and wound bed. Contamination of the tissue product and/or wound bed due to failure to ensure aseptic technique could result in local, regional, or systemic infection, partial or complete failure of graft take, healing, and/or regeneration, serious injury, and/or death. Failure to follow instructions may lead to sub-optimal outcomes and/or product failure. Pathology that would limit the blood supply and compromise healing, nonvascular surgical sites, and general medical condition should be considered when selecting patients for SkinTE. Such conditions may compromise successful outcomes or lead to sub-optimal results.

Potential adverse effects may include but are not limited to the following: local tissue, wound bed, regional tissue, or systemic infection, hypersensitive, allergic, or other immune response to the product or trace amounts of antibiotic retained from primary harvest, deleterious effects on potential surrounding or adjacent autologous, allogeneic, or xenogeneic grafts, skin substitutes, or other reconstructions including infection and/or failure of adjacent grafted material to take and heal, requirement for further surgical operations(s) and/or debridement, or death.